Evidence map›Paper›PMID 39094579›Full record

ArticleCell reports. Medicine2024

Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination.

William N Voss, Michael A Mallory, Patrick O Byrne, Jeffrey M Marchioni, Sean A Knudson, John M Powers, Sarah R Leist, Bernadeta Dadonaite, Douglas R Townsend, Jessica Kain and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human VProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

William N VossDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Michael A MalloryDepartment of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Patrick O ByrneDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Jeffrey M MarchioniDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Sean A KnudsonDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
John M PowersDepartment of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Sarah R LeistDepartment of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Bernadeta DadonaiteBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Douglas R TownsendDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Jessica KainDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Yimin HuangDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Ed SatterwhiteDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.
Izabella N CastilloDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Melissa MattocksDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Chelsea ParesiDepartment of Chemistry, The University of Texas at Austin, Austin, TX, USA.
Jennifer E MuntDepartment of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Trevor ScobeyDepartment of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Allison SeegerDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.
Lakshmanane PremkumarDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jesse D BloomBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA; Howard Hughes Medical Institute, Seattle, WA, USA.
George GeorgiouDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.
Jason S McLellanDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Ralph S BaricDepartment of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jason J LavinderDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA. Electronic address: jlavinder@utexas.edu.
Gregory C IppolitoDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA. Electronic address: gippolito@txbiomed.org.

Funding

Project 3: Serological Interactions with the Mucosal Innate Immune System Regulates COVID-19 Associated Tissue Damage.U54CA260543 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOLFGANG, MATTHEW C · 2020 to 2024
$9.8M
Structure, Function and Antigenicity of Coronavirus Spike ProteinsR01AI127521 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI MCLELLAN, JASON SCOTT, WARD, ANDREW BARRETT · 2017 to 2021
$3.1M
Prospectively characterizing the functional and antigenic effects of mutations to viral entry proteinsR01AI141707 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2018 to 2022
$2.1M
NCI NIH HHS U54 CA260543NIAID NIH HHS R01 AI127521NIAID NIH HHS R01 AI141707
6 · The paper itself

Abstract

We describe the molecular-level composition of polyclonal immunoglobulin G (IgG) anti-spike antibodies from ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, vaccination, or their combination ("hybrid immunity") at monoclonal resolution. Infection primarily triggers S2/N-terminal domain (NTD)-reactive antibodies, whereas vaccination mainly induces anti-receptor-binding domain (RBD) antibodies. This imprint persists after secondary exposures wherein >60% of ensuing hybrid immunity derives from the original IgG pool. Monoclonal constituents of the original IgG pool can increase breadth, affinity, and prevalence upon secondary exposures, as exemplified by the plasma antibody SC27. Following a breakthrough infection, vaccine-induced SC27 gained neutralization breadth and potency against SARS-CoV-2 variants and zoonotic viruses (half-maximal inhibitory concentration [IC

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19Immunoglobulin GSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationAntibodies, MonoclonalCOVID-19 VaccinesEpitopesFemaleHumansMaleAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesEpitopesImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibody feedbackbNAbbroadly neutralizing monoclonal antibodyCOVID-19cryo-EMhybrid immunityIg-seqimmunological imprintingplasmaSARS-CoV-2

Identifiers

PMID39094579
PMCPMC11384961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.